Obagi Medical’s Real-World Data Shows 94% Injector Approval for MagIQ Filler
Obagi Medical’s interim ALOHA program data shows 94% of over 300 injectors endorse its Saypha® MagIQ filler and 43% of patients also evaluating Obagi skincare. A 12-week open-label study demonstrated NU-GEN™ Cellular Renewal Serum can reverse skin age by up to six years, improving wrinkles, hyperpigmentation and firmness.
1. Interim ALOHA Program Results
Obagi Medical presented interim findings from its ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) real-world program involving over 300 practice sites. The data indicated that 94% of participating injectors believe Saypha® MagIQ filler complements their existing offerings, while 43% of patients in the program also began using Obagi skincare.
2. NU-GEN Serum Clinical Findings
A separate 12-week open-label trial evaluated NU-GEN™ Cellular Renewal Serum across nine skin aging markers. Results showed a visible reversal of skin age by up to six years, with significant improvements in wrinkles, hyperpigmentation, texture, firmness and radiance reported at the study’s conclusion.
3. Strategic Impact for Waldencast
These data reinforce Obagi Medical’s leadership in physician-dispensed aesthetic solutions and support Waldencast plc’s growth strategy in the professional skincare and injectable markets. Strong clinical and real-world validation may accelerate product adoption, potentially driving revenue growth and enhancing the company’s competitive position.